AstraZeneca, the British pharma company, has accepted about the potential side effects of Covid vaccine, as reported by The Telegraph. Covishield, the vaccines that had largely been administered in India, may lead to conditions leading to blood clots, low platelet count etc. Covishield was produced by the Indian Institute of India but was developed by AstraZeneca and Oxford University during the deadly Covid-19 pandemic.
There have been several speculations about Covid vaccines and their side effects. The British pharama company is already facing a major lawsuit in UK over claims that its vaccine caused severe injuries, and deaths in multiple cases.
In a document produced by the vaccine maker, they admitted that Covishield can “in very rare cases, cause TTS”. Thrombosis with Thrombocytopenia Syndrome (TTS) is a rare blood clot disorder.
TTs is a serious condition where there are blood clots (thrombosis) and low platelets count (thrombocytopenia). Platelets are important for healthy blood clot formation that prevents excessive bleeding. However, TTS can lead to unusual blood clot locations like in the brain or abdomen.
“TTS is thrombosis with thrombocytopenia syndrome, which is basically clot in blood vessels of the brain or elsewhere, along with a low platelet count. It is known to occur in very rare instances following certain types of vaccines and also from other causes. According to the WHO, adenovirus vector vaccines in particular have been rarely associated with this condition,” he told ANI.
“Although COVID vaccines have prevented numerous deaths, reports of these extremely rare but potentially serious immune mediated events have also been published in reputed journals,” Dr Jayadevan added.
For breaking news and live news updates, like us on Facebook or follow us on Twitter and Instagram. Read more on Latest Lifestyle News on India.com.
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts Cookies Policy.